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Abstract 
 
Objective: To examine the association between sleep duration and cardiometabolic risk factors among 
individuals with recently diagnosed type 2 diabetes (n=391). 
 
Methods: Sleep duration was derived using a combination of questionnaire and objective heart rate 
and movement sensing in the UK ADDITION-Plus study (2002-2007). Adjusted means were 
estimated for individual cardiometabolic risk factors and clustered cardiometabolic risk (CCMR) by 
five categories of sleep duration. 
 
Results: We observed a J-shaped association between sleep duration and CCMR – individuals 
sleeping 7-<8 hours had a significantly better CCMR profile than those sleeping ≥9 hours. 
Independent of physical activity and sedentary time, individuals sleeping 7-<8 hours had lower 
triacylglycerol (0.62 mmol/l [0.29, 1.06]) and higher HDL-cholesterol levels (0.23 mmol/l [0.16, 
0.30]) compared with those sleeping ≥9 hours, and a lower waist circumference (7.87 cm [6.06, 9.68]) 
and BMI (3.47 kg/m
2
 [2.69, 4.25]) than those sleeping <6 hours. Although sleeping 7-<8 hours was 
associated with lower levels of systolic- and diastolic- blood pressure, HbA1c, total cholesterol and 
LDL-cholesterol, these associations were not statistically significant.  
 
Conclusions: Sleep duration has a J-shaped association with CCMR in individuals with diabetes, 
independent of potential confounding. Health promotion interventions might highlight the importance 
of adequate sleep in this high risk population.  
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1. Introduction 
It is currently recommended that adults should aim to get 7 to 9 hours of sleep each day [1]. However, 
a large majority of adults report sleeping less than this, a trend which has become increasingly 
prevalent in modern society. Recent data from ‘The Great British Bedtime Report’ revealed that in 
2013 70% of the adult population slept for ≤7 hours, and 33% slept for <6 hours per night compared to 
27% in 2010 [2]. Sleep duration in adult Americans follows a similar declining trend [3]. In the last 
decade, an increasing number of laboratory and epidemiological studies have linked short sleep 
duration with increases in hunger and appetite [4], decreased glucose tolerance [5] and an increased 
risk of weight gain [6, 7], obesity [6, 7], hypertension [8, 9], type 2 diabetes [10] and cardiovascular 
outcomes [11].  
 
While laboratory studies provide important insights into the potential pathways linking acute short 
sleep duration with cardiovascular health, major limitations are that they are conducted in artificial 
settings and usually have small sample sizes [12]. Whether prolonged short sleep duration is 
associated with factors predisposing to cardiovascular disease in free-living populations remains 
unclear. Although a number of epidemiological studies have examined associations between habitual 
sleep duration and cardiovascular health outcomes, they have traditionally used self-report measures 
of sleep duration [13] which are prone to error and bias and which have only moderate agreement with 
objectively assessed sleep duration [14]. Furthermore, though physical activity and sedentary time 
may confound the association between sleep duration and cardiovascular health [15, 16], only a small 
number of studies have adjusted for self-reported physical activity [17, 18]; to our knowledge no 
studies have adjusted for objective measures of physical activity and sedentary time. These important 
limitations preclude a clear understanding of the potential role that sleep duration may have in 
cardiovascular health. Finally, few studies have examined the role of sleep duration among individuals 
with type 2 diabetes, who are, as a consequence, at higher risk of developing cardiovascular risk [17-
21]. Improved understanding of this relationship will inform future intervention programmes aimed at 
identifying and managing high-risk individuals.   
 
The objective of the current study was to quantify the association between sleep duration derived 
using a combination of self-report questionnaire and objectively measured free-living data and 
established cardiometabolic risk factors, independent of potential confounding by physical activity and 
sedentary time, among a population at high risk of developing cardiovascular disease.  
 
2. Methods 
The design and rationale for the ADDITION-Plus study has been reported previously (2002-2007) [22]. 
In brief, ADDITION-Plus is a randomised controlled trial nested within the intensive treatment arm of 
the ADDITION-Cambridge study, which evaluated the efficacy of a facilitator-led, theory-based 
behaviour change intervention for recently diagnosed type 2 diabetes patients. 34 general practices in 
East Anglia participated. Eligible individuals were those aged 40-69 years diagnosed with diabetes 
following screening in the ADDITION study or clinically diagnosed during the three previous years in 
participating GP surgeries. Exclusion criteria included women who were pregnant or lactating or 
anybody with a psychotic illness or an illness with a likely prognosis of less than one year. 478 out of 
1,109 eligible individuals agreed to participate in ADDITION-Plus and were individually randomised 
to receive either intensive treatment alone (n=239), or intensive treatment plus a facilitator-led 
individual behaviour change intervention (n=239). All participants gave written informed consent, and 
the study was approved by the Eastern Multi-Centre Research Ethics Committee (reference number: 
02/5/54). The trial is registered as ISRCTN 99175498. 
 
2.1. Assessment of physical activity and sleep duration  
Participants activity intensity was assessed using a combined heart-rate and movement sensor 
(Actiheart, CamNtech, Cambridge, UK) worn continuously for four days at 30-second resolution, as 
described in detail elsewhere [23]. A graded treadmill walk test was used to individually calibrate 
heart-rate, as described elsewhere [15, 24]. For participants who did not complete an individual 
calibration test, all valid calibration tests in the rest of the sample were used to derive an age, sex, 
beta-blocker, and sleeping heart-rate adjusted group calibration equation for the translation of heart-
rate to activity intensity. Heart-rate data collected during the free-living period were processed using 
noise classification followed by Gaussian robust regression [25] and average activity intensity (J min
-1
 
kg
-1
) was estimated using a branched equation framework [26]. Resulting time-series data were 
summarised into physical activity energy expenditure (PAEE; kJ kg
-1
 day
-1
) and sedentary time whilst 
minimising diurnal information bias caused by non-wear periods (segments of non-physiological data). 
Sedentary time was defined as a MET value (metabolic equivalent of task) of <1.5 in accordance with 
current convention [27] using the Oxford estimate of resting metabolic rate (RMR) to define 1 MET 
[28]. To derive sleep duration, time-series data from the combined heart-rate and movement sensor 
were summarised after constraining assessment to within each participant’s mean self-reported getting 
up and going to bed times (self-reported using open-ended questions asking “at what time do you 
normally get up?” and “at what time do you normally go to bed?” on weekdays and on weekend days 
[29]) in combination with the requirement that intensity was ≤1.04 METs. This intensity threshold was 
applied according to recent research demonstrating that values below this MET cut-point are 
symptomatic of being in a reclined posture (indicative of sleep) as opposed to a seated posture [30]. 
The appropriateness of this method was verified by visual inspection by overlaying self-reported 
getting up and going to bed times on the objective time-series data. 
 
2.2. Outcome measurements 
Body weight and height were measured in light clothing and without shoes using a scale (SECA, UK) 
and a fixed rigid stadiometer, respectively. BMI was calculated as weight in kilograms divided by 
height in metres squared (kg/m
2
). Waist circumference was calculated as the average of two 
measurements taken halfway between the lowest point of the rib cage and the anterior superior iliac 
crests while standing. Blood pressure was calculated as the mean of three measurements performed after 
10 minutes of rest and with participants seated with a cuff placed on the predominant arm at the level of 
the heart, using an automatic sphygmomanometer (Omron M4, UK). HbA1c was measured in venous 
samples using an ion-exchange high-performance liquid chromatography method (Tosoh Bioscience, 
Redditch, UK). Serum triacylglycerol, total cholesterol, HDL- and LDL-cholesterol were measured 
using enzymatic techniques (Dade Behring Dimension analyser, Newark, USA). All measures were 
carried out by trained staff following standard operating procedures and who were unaware of 
participants’ sleep patterns. 
 
A summary clustered cardiometabolic risk score (CCMR-score) was created, incorporating measures 
of central obesity (waist circumference), dyslipidaemia (fasting triacylglycerol and HDL-cholesterol), 
hypertension (systolic blood pressure) and hyperglycaemia (HbA1c). Individual measures were 
standardised (i.e. z-scores were computed: z = [value – mean]/SD) after log-transformation (ln) of 
triacylglycerol due to a non-normal distribution. Next, individual z-scores were summed after 
inverting HDL-cholesterol values. CCMR was also calculated without the inclusion of BMI (CCMR no 
BMI), thereby allowing examination of the association of sleep duration on CCMR independent of BMI. 
 
2.3. Covariates 
PAEE and sedentary time were assessed using combined heart-rate and movement sensing (see: 
Assessment of physical activity and sleep duration). Standardised self-report questionnaires were used 
to collect information on socio-demographic characteristics, smoking status and prescribed medication. 
Total energy and alcohol intake were assessed using a validated food frequency questionnaire [31]. As 
psychological disorders can contribute to chronic sleep deprivation, and are positively associated with 
weight gain [32], we adjusted for the mental components of health status using the short-form-36 (SF-
36) health survey questionnaire [33].  
 
Complete data on objectively measured sleep duration, PAEE, time spent sedentary, metabolic risk 
factors and potential confounding variables were available on 391 participants. 
 
2.4. Statistical analysis 
The data for this analysis were treated as a cohort and not analysed by trial arm because the 
intervention used in ADDITION-Plus was not designed to influence sleep duration and no evidence of 
interaction by trial arm was found in the proceeding multivariate analyses (all p-interaction ≥0.09). 
Descriptive characteristics of the participants were summarised by categories of sleep duration (<6 
hours, 6 to <7 hours, 7 to <8 hours, 8 to <9 hours and ≥9 hours) using means with SDs, medians with 
interquartile ranges or frequencies. P for trend, Kruskal-Wallis and chi
2
 tests were used to examine 
differences in participant characteristics across categories of sleep duration.  
 We examined associations between sleep duration categories (<6 hours, 6 to <7 hours, 7 to <8 hours, 8 
to <9 hours and ≥9 hours) and CCMR, CCMR no BMI, waist circumference, BMI, systolic- and 
diastolic- blood pressure, HbA1c, triacylglycerol, total cholesterol, and HDL- and LDL-cholesterol 
using multivariate linear regression analyses. Triacylglycerol values were log-transformed (ln) for 
statistical analysis due to a non-normal distribution. We estimated the adjusted means and 95% CIs of 
CCMR, CCMR no BMI, waist circumference, BMI, systolic- and diastolic- blood pressure, HbA1c, 
triacylglycerol (ln), total cholesterol, and HDL- and LDL-cholesterol for each sleep category and 
tested for linear and nonlinear trends across categories using the post-estimation polynomial ‘contrast’ 
command in Stata. We included potential confounders in the models based on previously published 
associations, biological reasoning and statistical associations between exposure and outcomes in the 
current dataset. All regression models are presented adjusted for age, sex and trial arm (age- sex 
adjusted) and adjusted for age, sex, trial arm, occupational socio-economic class, PAEE, time spent 
sedentary, smoking status, alcohol intake, day-time tiredness, mental health score and sleep affecting 
medication e.g. beta-blockers, sleeping tablets and minor tranquilisers [34] (multivariate adjusted). 
Triacylglycerol values were back-transformed and reported as adjusted geometric means and their 
95% CIs. When the outcome of interest was either blood pressure, HbA1c, triacylglycerol or HDL- and 
LDL-cholesterol, we additionally adjusted for use of anti-hypertensive, glucose lowering, or lipid-
lowering medication, respectively. For CCMR we adjusted for use of anti-hypertensive, glucose 
lowering and lipid-lowering medications and additionally for BMI when examining CCMR no BMI. The 
variance inflation factor did not exceed 4 in any of the models, indicating absence of multicollinearity. 
To investigate differences between sleep duration categories we used Dunnett’s significant difference 
post hoc test to compare each category of sleep duration with those sleeping 7 to <8 hours/night 
(comparison category). 7 to <8 hours/night of sleep was chosen as the comparison category a 
posteriori based on this category having the lowest CCMR risk profile. We formally examined 
whether associations between sleep duration categories and CVD risk factors were modified by sex by 
entering cross-product terms in the multivariate models. 
 
In sensitivity analyses we assessed whether our findings were sensitive to: 1) the inclusion of energy 
intake in all multivariate models, 2) inclusion of waist circumference as opposed to BMI in all 
multivariate models adjusted for BMI, and 3) using a cut-point of ≤1.04 METs for the definition of 
sleep as opposed to a cut-point of ≤1.00 MET. All statistical analyses were performed using Stata/SE 
13.1 (Stata-Corp, College Station, TX). 
 
3. Results 
The mean (SD) age of study participants was 60.3 (7.4) years. 97.7% of participants were of white 
European decent. 41.9% of participants reported having a managerial job. More men than women 
(n=248 vs. 143, respectively) met the inclusion criteria for the study and agreed to participate. Mean 
duration of diabetes did not differ across categories of sleep duration (P =0.43). The percentage of 
study participants who slept <6 hours and >9 hours per night was 11.3% and 5.9%, respectively. 
Table 1 shows the characteristics of the study population by categories of sleep duration. Compared 
with participants with short sleep durations, participants with longer sleep durations were older, were 
more likely to be female and were less likely to be employed in a managerial position. When 
expressed in absolute terms, both PAEE and sedentary time decreased across increasing sleep 
categories. In contrast, when expressed relative to hours awake, participants sleeping 7 to <8 
hours/day had the highest PAEE level and spent the lowest proportion of the day sedentary. Sleep 
duration was weakly inversely correlated with sedentary time (r = -0.22; p <0.001) and PAEE (r = -
0.26; p <0.001). Sedentary time was strongly inversely correlated with PAEE (r = -0.73; p <0.001). 
The mean duration of valid combined heart rate and movement sensing data was 4.02 (SD: 0.40) days. 
 
As shown in Table 2, after adjustment for age, sex and trial arm, participants sleeping 7 to <8 
hours/night had a lower CCMR and CCMR no BMI than all other sleep categories, which was 
significantly lower when compared with those sleeping ≥9 hours/night (p<0.05). The J-shaped 
associations between sleep duration and CCMR and CCMR no BMI remained after additional adjustment 
for other potential confounding factors including objectively assessed physical activity, sedentary time, 
feelings of daytime tiredness, sleep affecting medication (P-quadratic-trend: 0.004) and BMI in the 
CCMR no BMI model (P-quadratic-trend: 0.025). After multivariate adjustment, sleep duration was 
inversely associated with waist circumference and BMI (P-linear-trend both <0.001), such that 
participants sleeping 7 to <8 hours/night had a 7.9 cm lower waist circumference and 3.5 kg/m
2
 lower 
BMI than those sleeping <6 hours/night (p<0.05). In adjusted analyses, triacylglycerol levels were 
lowest among participants sleeping 7 to <8 hours/night, and were significantly lower when compared 
with those sleeping ≥9 hours/night (p<0.05). HDL-cholesterol levels did not differ across sleep 
categories except for individuals sleeping ≥9 hours/night, among whom levels were significantly 
lower than those sleeping 7 to <8 hours/night (mean 0.98 mmol/l [95% CI: 0.86, 1.11] vs. 1.21 mmol/l 
[95% CI: 1.16, 1.25], respectively). We found no consistent associations between sleep duration and 
systolic- or diastolic blood pressure, HbA1c, total cholesterol or LDL-cholesterol, although the lowest 
levels tended to be observed among those sleeping 7 to <8 hours/night.  
 
We found no evidence of interaction by sex (all p-values:≥0.08) except for the association with 
diastolic blood pressure (p-for-interaction: 0.03). When stratified by sex, men sleeping 6 to <7 
hours/night had a diastolic blood pressure 9.53 mmHg (95% CI: 5.29, 13.77) higher than women 
sleeping 6 to <7 hours/night; no other differences between men and women across sleep categories 
were found. Additional adjustment for total energy intake in the multivariate models did not materially 
change our findings (data not shown). Using a cut-point of ≤1.00 MET to define sleep, as opposed to a 
cut-point of ≤1.04 METs, did not materially change our findings (data not shown).  
 
4. Discussion 
 
This study demonstrates that patients with type 2 diabetes who sleep 7 to <8 hours per night have a 
better cardiometabolic risk profile, including measures of waist circumference, BMI, triacylglycerol 
and HDL-cholesterol than those who sleep fewer than 6 hours or more than 9 hours per night. To the 
best of our knowledge, this is the first epidemiological study to investigate the association between 
objectively measured sleep duration and a wide range of cardiovascular risk factors independent of 
potential confounding by objectively measured physical activity and sedentary time. Our findings 
support the hypothesis that sleep duration is a potentially important and modifiable behaviour related 
to cardiometabolic risk in individuals with type 2 diabetes who are at high risk of cardiovascular 
disease. 
 
An inverse association between sleep duration and anthropometric measures is consistent with 
previous literature. In a meta-analysis of 18 cross-sectional studies, which included a total of more 
than 604,000 adults [35], each additional hour of sleep was found to be associated with a pooled β-
coefficient for BMI of -0.35 kg/m
2
 (95% CI: -0.57, -0.12). Several [6, 7], but not all [36], prospective 
studies have also reported inverse associations between sleep duration and weight gain. For example, 
in the Quebec Family Study cohort, individuals sleeping 5-6 hours/day gained 1.98 (95% CI: 1.16, 
2.82) kg more than those sleeping an average of 7-8 hours/day, over a period of 6-years [6]. 
Additionally, the risk for developing obesity was shown to be 27% higher among short duration 
sleepers compared with those sleeping 7-8 hours/day after 6-years of follow-up. Several studies have 
indicated that a J-shaped association may exist between sleep duration and weight in healthy adults, 
such that sleeping more than 8 hours/day is similarly related to excess weight as sleeping too few 
hours [37]. However, we did not find strong evidence indicative of deviation from linearity, which is 
consistent with a recent study in individuals with type 2 diabetes [18]. Previous studies have found 
that sleep restriction can adversely affect glucose metabolism in response to a glucose challenge, but 
not fasting glucose or insulin levels [5, 38]. A recent cross-sectional study also reported no association 
between sleep duration and fasting glucose, insulin or the homeostatic model assessment (HOMA) 
index in individuals with or without type 2 diabetes [20], which is consistent with our finding of no 
clear association between sleep duration and HbA1c.  
 
Previous studies examining the association between sleep duration and lipid levels have yielded mixed 
results [17, 39, 40]. Consistent with our findings, it has previously been shown that longer sleep 
durations are associated with relatively  higher triacylglycerol levels and lower HDL-cholesterol levels 
[40]. In a cross-sectional study comprised mostly of participants free from diabetes, it was also 
observed that individuals sleeping >8 hours per night had a borderline significantly lower HDL-
cholesterol level relative to individuals sleeping 7-8 hours per night [39]. However, in a similar study 
to ours, but which included only women with diabetes, Williams et al [17] found no association 
between sleep duration and lipid levels, although HDL-cholesterol levels did appear to increase with 
increasing sleep duration, but only among normotensive individuals.  
 
In the NHANES study, sleeping ≤5 hours compared with sleeping 7-8 hours per night was associated 
with a 60% higher risk of hypertension in healthy adults aged 32-59 years, but not among individuals 
aged over 60 years [8]. In a prospective analysis of sleep duration and hypertension in the Whitehall-II 
study [41], a non-significant inverse association between sleep duration and hypertension was found 
among women, but not men, sleeping ≤5 hours per night. In our study, we observed no clear 
associations between sleep duration and blood pressure across sleep duration categories. Explanations 
for differences between study findings, other than diabetes status, might be the method used for sleep 
assessment, differences in the age of the participants and differences in covariate selection and 
adjustment. 
 
The biological mechanisms underlying the relationship between short sleep duration and 
cardiometabolic risk factors remain to be fully elucidated, but several plausible mechanisms have been 
suggested in relation to the risk of overweight and obesity [12]. One plausible mechanism to explain 
our finding is provided by Spiegel et al [4]. In a randomised cross-over trial which involved two days 
of sleep restriction preceded/followed by two days of sleep extension, Spiegel et al showed that the 
appetite-stimulating hormone, ghrelin, increased by 28% whereas the appetite suppressing hormone, 
leptin, decreased by 18% following the two days of sleep restriction. Resultantly, appetite increased by 
23%, especially for calorie-dense, high carbohydrate foods. To examine whether the association 
between sleep duration and anthropometric measures was mediated by energy intake in our analyses 
we additionally adjusted for total energy intake, but this did not materially change our findings, 
suggesting that our findings are unlikely explained by self-reported increased food intake. As short 
sleep duration can also increase feelings of fatigue [42], which may lead to relative reductions in 
physical activity [43] and resting metabolic rate [44], this may also partly explain the associations we 
observed. Indeed, we did find that participants sleeping 7 to <8 hours per night tended to be more 
physically active and less sedentary than those sleeping fewer than 7 hours per night (when expressed 
relative to time awake). 
 
The current study has a number of strengths. First, to derive sleep duration we used a combination of 
self-report questionnaire and objectively measured free-living data from a combined heart rate and 
movement sensor worn continually for four days, unlike previous studies which have tended to use 
self-report data only [13]. While this method has not been used previously, our MET definition of 
sleep has been shown to be consistent with a posture indicative of sleep as opposed to a seated posture 
[30]. MET thresholds are commonly used in the scientific literature to define both low energy 
expenditure activities such as reading and watching television as well as vigorous intensity activities 
such as running [45]. In addition, combining self-report and objective data for the assessment of sleep 
duration has been recommended in order to overcome the limitations of subjective and objective data 
when used in isolation [46]. Unlike previous studies, a major strength of our study was that we 
accounted for objectively measured physical activity and sedentary time in our models, both of which 
differ by sleep duration. Our study also has a number of limitations. The cross-sectional analysis of 
our study precludes inference of the direction or causal nature of the observed associations. As such, it 
is equally plausible that obesity may have influenced sleep duration. However, our results are 
consistent with the epidemiological evidence indicating that short sleep duration is adversely 
associated with cardiovascular risk factors [6-9, 13, 33, 47]. We were unable to account for potential 
confounding by sleep apnoea, the prevalence of which may be as high as 83% in patients with type 2 
diabetes [48]. Nevertheless, we have adjusted our analyses for several factors known to be associated 
with sleep apnoea, and which are currently used for the screening of sleep apnoea (i.e. Berlin 
Questionnaire [49]), including age, sex, feelings of daytime tiredness and BMI. Finally, although we 
included many potential confounding variables we cannot exclude the possibility of residual 
confounding, for example by variation in day-time napping. To address the limitations of the current 
study future well designed prospective studies are needed which have measures of sleep duration, 
physical activity, sedentary time and which also account for potential confounding by sleep apnoea 
and sleep quality. 
 
In summary, our results provide further evidence of the potentially important role of sleep on 
cardiometabolic risk in people with type 2 diabetes. Examining the prospective association between 
sleep duration and a wide range of cardiometabolic risk factors, and the likely multiple determinants of 
sleep duration, will be important for improving the future design of lifestyle interventions aimed at 
reducing cardiovascular morbidity in this high risk population.  
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Table 1. Characteristics of the UK ADDITION-Plus study (2002-2007) participants according to sleep duration 
 
 Sleep duration (hours/day)  
 <6 6 to <7 7 to <8 8 to <9 ≥9 P value 
N 44 102 138 84 23  
Sleep duration (hours/day) 5.2 (0.7) 6.6 (0.3) 7.4 (0.3) 8.4 (0.3) 9.5 (0.7)  
Age (years) 58.6 (6.5) 58.5 (7.4) 60.3 (7.2) 61.9 (7.5) 65.9 (5.4) <0.001 
Male (%) 77 75 66 48 26 <0.001 
Duration of diabetes (years) 2.1 (2.3) 2.2 (1.7) 2.0 (1.8) 2.4 (2.1) 2.4 (2.2) 0.43 
Sex-adjusted energy intake (kcal/ day-1) 1762 (492) 1834 (494) 1735 (490) 1651 (499) 1662 (499) 0.15 
Total PAEE (kJ kg-1 day-1) 40.7 (17.7) 36.2 (17.4) 36.7 (16.2) 29.7 (16.0) 22.6 (8.2) <0.001 
PAEE/hour (kJ kg-1 woken hour-1) 2.17 (0.95) 2.07 (0.99) 2.22 (0.97) 1.91 (1.02) 1.55 (0.55) 0.005 
Total sedentary time (hours/day) 11.1 (2.8) 10.9 (2.6) 9.4 (2.5) 9.8 (2.0) 9.6 (1.8) <0.001 
Percentage woken hour-1 sedentary (%) 0.59 (0.15) 0.62 (0.15) 0.57 (0.15) 0.63 (0.13) 0.66 (0.12) 0.008 
Managerial socio-economic class (%) 41 51 44 32 26 0.02 
Current smoker (%) 20 19 10 10 17 0.15 
Sex-adjusted alcohol intake (g/d) 11.2 (1.6) 6.5 (1.0) 6.6 (0.9) 9.6 (1.1) 7.8 (2.2) 0.03 
Tiredness during the day (%) 34 32 23 27 17 0.33 
Mental health score 73 (22) 78 (16) 79 (18) 75 (18) 80 (14) 0.27 
Sleep medication user (%) 14 14 12 21 9 0.29 
Use anti-hypertensive drugs (%) 70 76 67 73 87 0.28 
Use hypoglycaemic drugs (%) 50 56 50 49 52 0.88 
Use lipid-lowering drugs (%) 73 76 78 74 74 0.95 
Values are expressed as means (SD) unless stated otherwise. P-values are from P-trend, Kruskal-Wallis and chi2 tests, as appropriate.  
IQR = interquartile range. PAEE = physical activity energy expenditure. 
 
 
Table 2. Adjusted means (95% CIs) for cardiovascular risk factors according to sleep duration categories for UK ADDITION-Plus study (2002-2007) 
participants 
 
 Sleep duration (hours/day)   
 <6 6 to <7 7 to <8 8 to <9 ≥9 P for 
linear 
trend 
P for 
quadratic 
trend 
N 44 102 138 84 23   
CCMR-score        
Age- and sex adjusted 0.17 (-0.58, 0.92) 0.08 (-0.42, 0.58) -0.44 (-0.86, -0.02) -0.20 (-0.74, 0.35) 1.33 (0.27, 2.39)* 0.154 0.005 
Multivariate adjusted 0.53 (-0.26, 1.32) 0.10 (-0.41, 0.61) -0.39 (-0.81, 0.02) -0.37 (-0.93, 0.18) 0.92 (-0.16, 2.00) 0.839 0.004 
CCMR no BMI        
Age- and sex adjusted -0.09 (-0.73, 0.55) 0.07 (-0.35, 0.49) -0.34 (-0.69, 0.02) -0.09 (-0.55, 0.37) 1.29 (0.39, 2.19)* 0.032 0.011 
Multivariate adjusted -0.05 (-0.74, 0.64) -0.02 (-0.46, 0.43) -0.29 (-0.65, 0.07) -0.07 (-0.55, 0.42) 1.22 (0.28, 2.17)* 0.075 0.013 
Multivariate + BMI -0.24 (-0.94, 0.46) -0.06 (-0.50, 0.38) -0.27 (-0.63, 0.09) 0.02 (-0.46, 0.51) 1.31 (0.37, 2.25)* 0.024 0.025 
Waist (cm)        
Age- and sex adjusted 112.92 (109.11, 116.72) 109.95 (107.42, 112.48) 108.03 (105.90, 110.16) 107.41 (104.62, 110.19) 108.50 (103.08, 113.92) 0.118 0.193 
Multivariate adjusted 116.18 (112.38, 119.98)* 111.08 (108.64, 113.53) 108.31 (106.32, 110.30) 104.98 (102.28, 107.67) 104.42 (99.19, 109.64) <0.001 0.201 
BMI (kg/m2)        
Age- and sex adjusted 33.60 (31.97, 35.23) 32.42 (31.34, 33.51) 31.74 (30.82, 32.65) 31.57 (30.38, 32.77) 32.35 (30.03, 34.68) 0.285 0.153 
Multivariate adjusted 35.23 (33.59, 36.88)* 33.00 (31.94, 34.06) 31.76 (30.90, 32.63) 30.46 (29.29, 31.62) 30.57 (28.30, 32.83) <0.001 0.110 
Systolic BP (mmHg)        
Age- and sex adjusted 130.40 (125.43, 135.38) 129.44 (126.11, 132.76) 129.93 (127.13, 132.73) 130.11 (126.47, 133.75) 131.12 (124.03, 138.21) 0.825 0.701 
Multivariate adjusted 132.45 (127.03, 137.87) 130.28 (126.77, 133.78) 129.60 (126.74, 132.46) 129.02 (125.17, 132.86) 129.48 (122.04, 136.92) 0.513 0.572 
Multivariate + BMI 132.48 (126.94, 138.02) 130.29 (126.76, 133.81) 129.60 (126.73, 132.46) 129.00 (125.12, 132.89) 129.47 (121.99, 136.94) 0.515 0.571 
Diastolic BP (mmHg)        
Age- and sex adjusted 77.82 (75.15, 80.49) 74.75 (72.97, 76.53) 76.54 (75.04, 78.04) 76.20 (74.25, 78.15) 76.69 (72.89, 80.50) 0.875 0.325 
Multivariate adjusted 78.78 (75.87, 81.70) 75.28 (73.39, 77.17) 76.18 (74.64, 77.72) 75.79 (73.72, 77.85) 76.18 (72.17, 80.18) 0.427 0.205 
Multivariate + BMI 78.44 (75.47, 81.41) 75.20 (73.31, 77.09) 76.22 (74.68, 77.76) 75.96 (73.87, 78.04) 76.34 (72.32, 80.35) 0.567 0.245 
HbA1c (%)        
Age- and sex adjusted 6.63 (6.36, 6.90) 6.80 (6.62, 6.97) 6.53 (6.38, 6.68) 6.63 (6.44, 6.83) 6.79 (6.41, 7.17) 0.750 0.484 
Multivariate adjusted 6.63 (6.36, 6.90) 6.74 (6.57, 6.92) 6.56 (6.42, 6.71) 6.64 (6.44, 6.83) 6.79 (6.42, 7.17) 0.688 0.482 
Multivariate + BMI 6.60 (6.32, 6.88) 6.74 (6.56, 6.91) 6.57 (6.43, 6.71) 6.65 (6.46, 6.85) 6.81 (6.43, 7.18) 0.551 0.546 
Triacylglycerol (mmol/l) 1        
Age- and sex adjusted 1.75 (1.49, 2.05) 1.63 (1.46, 1.80) 1.55 (1.42, 1.70) 1.67 (1.48, 1.86) 2.12 (1.70, 2.66)* 0.175 0.014 
Multivariate adjusted 1.66 (1.40, 1.97) 1.58 (1.41, 1.76) 1.58 (1.45, 1.73) 1.73 (1.53, 1.95) 2.16 (1.71, 2.75)* 0.075 0.035 
Multivariate + BMI 1.59 (1.33, 1.89) 1.56 (1.40, 1.74) 1.59 (1.46, 1.74) 1.76 (1.56, 1.99) 2.21 (1.75, 2.80)* 0.026 0.059 
Total cholesterol (mmol/l)        
Age- and sex adjusted 4.40 (4.14, 4.66) 4.22 (4.05, 4.39) 4.25 (4.11, 4.40) 4.39 (4.20, 4.57) 4.34 (3.97, 4.71) 0.919 0.440 
Multivariate adjusted 4.30 (4.04, 4.56) 4.21 (4.04, 4.38) 4.29 (4.15, 4.42) 4.41 (4.22, 4.59) 4.30 (3.95, 4.66) 0.696 0.958 
Multivariate + BMI 4.29 (4.03, 4.56) 4.21 (4.04, 4.37) 4.29 (4.15, 4.42) 4.41 (4.22, 4.60) 4.31 (3.95, 4.67) 0.664 0.977 
HDL-cholesterol (mmol/l)        
Age- and sex adjusted 1.23 (1.15, 1.32) 1.18 (1.12, 1.23) 1.21 (1.16, 1.25) 1.21 (1.15, 1.27) 0.99 (0.87, 1.10)* 0.004 0.023 
Multivariate adjusted 1.23 (1.14, 1.32) 1.19 (1.13, 1.25) 1.21 (1.16, 1.25) 1.20 (1.13, 1.26) 0.98 (0.86, 1.11)* 0.009 0.018 
Multivariate + BMI 1.25 (1.16, 1.34) 1.20 (1.14, 1.26) 1.20 (1.15, 1.25) 1.18 (1.12, 1.25) 0.97 (0.85, 1.09)* 0.002 0.031 
LDL-cholesterol (mmol/l)        
Age- and sex adjusted 2.26 (2.02, 2.49) 2.28 (2.12, 2.43) 2.28 (2.15, 2.41) 2.38 (2.22, 2.55) 2.38 (2.05, 2.70) 0.424 0.902 
Multivariate adjusted 2.20 (1.97, 2.42) 2.27 (2.13, 2.42) 2.31 (2.20, 2.43) 2.37 (2.22, 2.53) 2.33 (2.03, 2.63) 0.415 0.580 
Multivariate + BMI 2.21 (1.98, 2.43) 2.28 (2.13, 2.42) 2.31 (2.19, 2.43) 2.37 (2.21, 2.53) 2.33 (2.03, 2.63) 0.463 0.604 
Numbers in parentheses represent the 95% Confidence Intervals.  
Age- and sex adjusted models also included adjustment for trial arm. Multivariate adjusted models included age, sex, trial arm, occupational socio-economic class, PAEE, sedentary time, smoking status, 
alcohol consumption, self-reported feelings of tiredness, mental health score and sleep affecting medication. 
Systolic- and diastolic blood pressure were additionally adjusted for prescription of anti-hypertensive drugs; HbA1c was additionally adjusted for prescription of glucose lowering drugs; triacylglycerol, 
total cholesterol, HDL- and LDL-cholesterol were additionally adjusted for prescription of lipid-lowering drugs. 
1 Data are geometric means (95% CIs) 
* Denotes significant difference from those sleeping 7 to <8 hours/night at p<0.05 using Dunnett’s significant difference comparison. 
 
